Shane DiGiovanna Act
Sponsored By: Representative Landsman, Greg [D-OH-1]
Introduced
Summary
Would require Medicaid to cover wound care for people with epidermolysis bullosa through a nationwide two-year demonstration. It would test mandatory coverage of specific wound supplies and some over-the-counter medicines and evaluate effects on spending and health outcomes.
Show full summary
- Families and people with epidermolysis bullosa: Would get Medicaid coverage for wound care supplies and certain medicines, including over-the-counter antihistamines, acetaminophen, nonsteroidal anti-inflammatory drugs, antiseptics, zinc oxide, antibiotic ointments, wound dressings, gauze, and bandage retainers.
- State Medicaid programs and HHS: The Secretary of Health and Human Services would run the demonstration nationwide through State plans or waivers and must start it within one year of enactment.
- Congress and policymakers: The Secretary would submit a report within one year after the demonstration ends evaluating program expenditures (including avoided treatments), comparing health outcomes to the period before the demonstration, and offering recommendations to prevent hospitalizations.
Your PRIA Score
Personalized for You
How does this bill affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
More Medicaid wound care for EB
This bill would require the HHS Secretary to run a 2-year, nationwide Medicaid demonstration starting no later than 1 year after enactment. The demonstration would require states to include certain wound care items and services as mandatory Medicaid medical assistance for people with epidermolysis bullosa (EB) eligible under section 1902(a)(10)(A)(i). Covered items would include over-the-counter antihistamines; acetaminophen; nonsteroidal anti-inflammatory drugs; antiseptics; zinc oxide; antibiotic ointments; and necessary wound supplies such as primary and secondary dressings, gauze, and bandage retainers. Not later than one year after the demonstration ends, the Secretary would report to Congress on Medicaid spending for EB patients, health outcomes compared to before the demonstration, and recommendations to prevent EB-related hospitalizations. If passed, this could lower out-of-pocket costs for Medicaid enrollees with EB and could help avoid costly hospital stays.
Sponsors & CoSponsors
Sponsor
Landsman, Greg [D-OH-1]
OH • D
Cosponsors
Rep. Gottheimer, Josh [D-NJ-5]
NJ • D
Sponsored 3/16/2026
Rep. Schneider, Bradley Scott [D-IL-10]
IL • D
Sponsored 3/17/2026
Rep. Sherman, Brad [D-CA-32]
CA • D
Sponsored 3/17/2026
Rep. Dingell, Debbie [D-MI-6]
MI • D
Sponsored 3/18/2026
Pelosi
CA • D
Sponsored 4/2/2026
Roll Call Votes
No roll call votes available for this bill.
View on Congress.gov